Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. [electronic resource]
Producer: 20170613Description: 42-51 p. digitalISSN:- 1474-5488
- Aged
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Benzodiazepinones -- therapeutic use
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Neuroendocrine -- drug therapy
- Dose-Response Relationship, Drug
- Female
- Follow-Up Studies
- Humans
- Immunoconjugates -- pharmacology
- Intracellular Signaling Peptides and Proteins -- immunology
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Membrane Proteins -- immunology
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Prognosis
- Small Cell Lung Carcinoma -- drug therapy
- Survival Rate
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.